Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
36.12
+0.59 (1.66%)
Nov 20, 2024, 4:00 PM EST - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees as of December 31, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
$999,957
Profits / Employee
$91,583
Market Cap
1.99B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Evotec SE | 5,061 |
Tandem Diabetes Care | 2,400 |
NeoGenomics | 2,100 |
Astrana Health | 1,800 |
GeneDx Holdings | 1,000 |
Beam Therapeutics | 436 |
Wave Life Sciences | 268 |
SUPN News
- 7 days ago - Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 8 days ago - Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth - Seeking Alpha
- 16 days ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - GlobeNewsWire
- 4 weeks ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire
- 5 weeks ago - Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree - GlobeNewsWire